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The 2013 ACC/AHA Guideline on the
Treatment of Blood Cholesterol*Nanette K. Wenger, MDSEE PAGE 2183
I n the topsy-turvy world of Lewis Carroll’s Alice inWonderland (1), the Cheshire Cat said, “only afew ﬁnd the way, some don’t recognize it when
they do—some . don’t ever want to.” Such was the
status of many healthcare providers and patients in
November 2013 at the issuance of the 2013 American
College of Cardiology/American Heart Association
Guideline on the Treatment of Blood Cholesterol to
Reduce Atherosclerotic Cardiovascular Risk in Adults
(2). This was coupled with the Guideline on the
Assessment of Cardiovascular Risk (3), using a new
risk assessment calculator, the Pooled Cohort Equa-
tions (4), to estimate atherosclerotic cardiovascular
disease (ASCVD) risk for adults aged 40 to 75 years
in the primary prevention setting. ASCVD incorpo-
rates stroke events in addition to coronary heart dis-
ease events and includes serious nonfatal events, as
well as mortality; these additions are designed to
reduce disability.
Guideline highlights include the following: focus
on managing ASCVD due to elevated low-density li-
poprotein cholesterol (LDL-C); citation of inadequate
evidence to support raising high-density lipoprotein
cholesterol or lowering triglyceride levels; delinea-
tion of 4 patient groups at increased absolute ASCVD
risk and recommendation of moderate-intensity or
high-intensity statins, depending on underlying risk*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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LDL-C targets.In this issue of the Journal, Maddox et al. (5) offer
insights from the NCDR PINNACLE (National Cardio-
vascular Data Registry Practice Innovation and Clin-
ical Excellence) on implications of these guidelines
for contemporary treatment and testing in cardio-
vascular practice. Data were derived from more than a
million patients in 111 cardiology ofﬁce practices
(from 2008 to 2012) with hypertension, coronary ar-
tery disease, heart failure, and/or atrial ﬁbrillation.
Likely owing to these patient subsets in self-selected
cardiology practices, >90% of the population is a
secondary prevention cohort, and thus the paper
does not address a major focus of the controversy
regarding the guideline, that is, primary prevention.
Nonetheless, one-third of statin-eligible patients
were not receiving statin therapy, and >20% received
currently not recommended nonstatin lipid-lowering
therapies. As cited in the guideline, nonstatin lipid-
lowering therapies lacked beneﬁt, as conﬁrmed
by the HPS2-THRIVE (Heart Protection Study 2—
Treatment of HDL to Reduce the Incidence of
Vascular Events) trial, where niacin plus laropiprant
lacked efﬁcacy and conferred risk (6). Analysis of this
treatment gap in general medical practices may
reveal even greater opportunities for enhancing
clinical care quality. Not captured in this database are
speciﬁc statin drugs and doses, although statin
therapy intensity is a new guideline aspect. Despite
their pronounced beneﬁt in the diabetic population,
36% of diabetic patients in the PINNACLE registry
were not receiving a statin, and this diabetic statin
beneﬁt may have been underestimated in a car-
diac population. Diabetic patients in endocrinology/
internal medicine/primary care practices may more
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ously, substantial differences between primary care
(the guideline’s target audience) and cardiology
practices are likely.
The guideline advises LDL-C testing to assess
adherence to statin therapy, but not for treatment to
target; however, 20% of PINNACLE registry patients
received currently not recommended repeat LDL-C
testing. On the basis of these ﬁndings, others will
likely examine the overall net cost effect of the new
guideline related to increased cost of statin use,
reduced cost for nonstatin therapies, reduced use
of statin and nonstatin therapies among patients
without indications, and reduced costs of LDL-C
testing, as well as potential savings from reduced
cardiovascular event occurrences.
A limitation of the guideline that selectively dis-
advantages older adults is that they were virtually
absent in the randomized controlled trial data that
informed the guideline. Except for PROSPER (Pro-
spective Study of Pravastatin in the Elderly at
Risk) (7), which enrolled 8,804 patients aged 70 to
82 years, and SAGE (Study Addressing Goals in
the Elderly) (8), with 893 patients 65 to 85 years
of age, only 20% to 30% of most primary and sec-
ondary prevention lipid trial participants were older
than age 70 years (9,10). The contemporary statin
treatment-risk paradox is striking; despite the high
attributable risk of hypercholesterolemia at elderly
age, and the statin-associated reduction in all-cause
mortality in this population (10), statin use declines
sharply at elderly age. This is despite SAGE’s
demonstration of greater beneﬁt in older patients
with high-intensity versus moderate-intensity statin
therapy. PROSPER showed a 24% coronary mortality
decrease for statin versus placebo. Because the ran-
domized controlled trial enrolled few older adults
(>75 years), this paucity of evidence enabled only a
secondary prevention recommendation for a
moderate-intensity statin. The PINNACLE registry
data offer little further elucidation. The mean
PINNACLE patients’ age was 65.2 years, and only
29.9% were in the Medicare category. The Pooled
Cohort Equations provide no ASCVD estimate for
those older than age 75 years, who have the highest
absolute ASCVD event risk, nor did its antecedent,
the Framingham Risk Score. The 2004 update to the
National Cholesterol Education Program Adult
Treatment Panel III guideline explicitly conﬁrmed
that older persons beneﬁt from therapeutic LDL-C
lowering (11).
Herein is the window of opportunity for clinician-
patient discussions and shared decision making.
For the functional elderly adult with fewcomorbidities, but the highest ASCVD event risk,
continuing or initiating high-intensity statins appears
prudent, given their documented beneﬁt to safely
reduce ASCVD morbidity and mortality. On the con-
trary, any statin as the 11th or 12th medication for a
frail elderly adult with multiple comorbidities and
polypharmacy risks appears of limited beneﬁt.
Remember also that the Pooled Cohort Equations
provide guidance only for non-Hispanic whites and
for blacks. Data are lacking for South Asians, many of
whom sustain outcome events and mortality prior to
age 40 years. Vulnerable populations merit special
attention where observational studies or expert
opinion may be all that is currently available. Women
with hypertensive and diabetic complications of
pregnancy may develop adverse risk proﬁles shortly
after the pregnancy (12). Women with systemic
autoimmune disorders (13) are at increased ASCVD
risk. We must avoid suggesting that these high-risk
populations await their 40th birthdays for risk
assessment and appropriate interventions. Age-based
discrimination at both ends of the spectrum poses a
potentially serious challenge.
And what of patients and goals? How does lack of
an LDL-C target relate to motivation to change, or to
systems designed to improve adherence to recom-
mended therapies? We employ heart health goals for
body mass index, steps/day of exercise, hemoglobin
A1c, and blood pressure. Why is LDL-C an orphan?
LDL-C measurement is recommended for ascertaining
therapy adherence, and the behavioral literature cites
the importance of goal-setting to enhancing adher-
ence (14). The REACH (Reduction of Athero-
thrombosis for Continued Health Registry) report (15)
conﬁrms the association of increased adverse events
with nonadherence to secondary prevention thera-
pies and recommends targeted interventions for
high-risk populations; goal-setting and periodic
reassessment may be components of such in-
terventions. Correlates of LDL-C level and ASCVD
events are abundant (16), even at elderly age, and in
both primary and secondary prevention settings,
without evidence of an LDL-C threshold in the
170,000 Cholesterol Treatment Trialists’ Collabora-
tion participants (17). This epidemiologic evidence
should help guide physician-patient conversations
addressing LDL-C management and related beneﬁts
and risks.
In contrast, the European Guidelines on cardio-
vascular disease prevention in clinical practice
(version 2012) recommend intervention strategies as a
function of total cardiovascular risk (based on SCORE
[Systematic COronary Risk Evaluation]) calculations
and LDL-C levels; they identify no differences
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of cholesterol lowering, even among individuals >75
years of age. LDL-C is the recommended primary lipid
analysis for screening and risk estimation, as well as
the treatment target (18). The International Athero-
sclerosis Society also uses LDL-C targets based on risk
status with LDL-C as the major target for lipid-
lowering therapy and advises statins as the initial
pharmacological intervention (19).
The guideline addresses the 50% anticipated LDL-C
reduction with a high-intensity statin and 30%
to <50% reduction with a moderate-intensity statin.Guidance is needed for adherent patients who fail to
attain this estimated percentage LDL-C reduction.
Patient-provider conversations should address in-
creasing statin intensity and/or dosage versus adding
a nonstatin drug.
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